Readership
Advanced Practice Nurses, Allergists, Allied Health Professionals, Anesthesiologists, Cardiologists, Caregivers, Critical Care Nurses, Critical Care Physicians, Dermatologists, Emergency Nurses, Emergency Physicians, Endocrinologists, Family Practice Physicians, Gastroenterologists, General Practitioners, Geriatricians, Gynecologists, Hematologists, Hepatologists, Hospice Nurses, Infectious Disease Specialists, Internists, Neonatologists, Nephrologists, Neurologists, Nurse Practitioners, Obstetricians, Oncologists, Ophthalmologists, Pain Specialists, Pathologists, Patients, Pediatricians, Perinatologists, Pharmacists, Pharmacologists, Physicians, Primary Care Physicians, Psychiatrists, Pulmonologists, Radiation Oncologists, Researchers, Rheumatologists, Scientists, Urologists
Scope
Drugs promotes optimum pharmacotherapy by providing a programme of review and original research articles on the most important aspects of clinical pharmacology and therapeutics. The Journal includes:
- Leading/current opinion articles providing an overview of contentious or emerging issues.
- Definitive reviews of drugs and drug classes, and their place in disease management.
- Therapy in Practice articles including recommendations for specific clinical situations.
- High-quality, well designed, original clinical research.
- Adis Drug Evaluations reviewing the properties and place in therapy of both newer and established drugs.
- AdisInsight Reports summarising development at first global approval.
Additional enhanced features (including slide sets, videos and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in Drugs may be accompanied by plain language summaries to assist readers in understanding important medical advances.
All manuscripts are subject to peer review by international experts. Letters to the editor are welcomed and will be considered for publication.
Stay up to date with the latest developments in therapeutics by reading the world’s most respected source of authoritative drug information. For over 40 years Drugs has been the definitive journal of drugs and therapeutics, promoting optimum pharmacotherapy by publishing reviews and original research authored by leading international clinicians and researchers to support clinical decision-making.
Through a rigorous and comprehensive program of peer-reviewed evaluations, Drugs provides detailed and objective analysis covering the full spectrum of new and established drug therapies in all disease areas.
The journal Also offers the ability to create digital features as well as host them.